Keyword: University of Pennsylvania
The cash sets ex-Novartis executive Usman “Oz” Azam up to hustle Tmunity's pipeline of T cell-based immunotherapies through clinical development.
The past week ushered in news about a toxin in scorpion venom that may relieve RA and a skin bacterium with anti-cancer powers.
Targeting a "highly prevalent" antigen could address the heterogeneity of glioblastomas.
Delivering gut microbes to mice can boost antibodies that shield them against sepsis.
The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.
The deal gives Arrakis rights to families of compounds that bind to three-way junctions found in folded RNA.
This past week saw new discoveries in treating heart failure, targeting Zika and dengue with one drug and inhibiting a cancer-promoting enzyme.
PARP inhibitor Lynparza may be able to kill cancer cells that don’t have BRCA mutations—provided it’s paired with a helper compound.
A multipronged immune attack that includes CAR-T treatments may be needed to fight glioblastoma, Penn scientists suggest.
This past week ushered in new discoveries in flu prevention, pancreatic cancer and HIV.